Therefore, GH does appear to influence MITF-regulated melanogenesis pathways in human melanoma cells, albeit in a cell-line specific and drug-specific manner, which could be a critical determinant in the choice of combination therapies with GHR-antagonism as an approach to combat cancer drug resistance. This evidence concerns the gene GH1 and cancer.